UBS Analysts Give Bayer (BAYN) a €125.00 Price Target
Bayer (FRA:BAYN) received a €125.00 ($148.81) target price from equities researchers at UBS in a report released on Thursday, www.boersen-zeitung.de reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. UBS’s price target would suggest a potential upside of 20.25% from the company’s previous close.
Other equities research analysts have also issued research reports about the stock. Barclays set a €100.00 ($119.05) target price on shares of Bayer and gave the stock a “sell” rating in a report on Wednesday. Warburg Research set a €121.00 ($144.05) target price on shares of Bayer and gave the stock a “buy” rating in a report on Wednesday, September 13th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Bayer in a report on Friday, October 20th. Independent Research set a €120.00 ($142.86) target price on shares of Bayer and gave the stock a “neutral” rating in a report on Wednesday, August 23rd. Finally, Deutsche Bank set a €124.00 ($147.62) target price on shares of Bayer and gave the stock a “buy” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of €122.19 ($145.46).
Shares of Bayer (FRA:BAYN) traded down €0.90 ($1.07) during trading on Thursday, reaching €103.95 ($123.75). 861,469 shares of the company’s stock traded hands. Bayer has a 12-month low of €86.60 ($103.10) and a 12-month high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.